Skip to main content
Top

International Journal of Clinical Oncology

Issue 6/2022

Content (12 Articles)

Open Access Tuberculosis Original Article

Exosomal LncRNA RP5-977B1 as a novel minimally invasive biomarker for diagnosis and prognosis in non-small cell lung cancer

Ling Min, Ting Zhu, Bo Lv, Taixue An, Qichao Zhang, Yanyan Shang, Zhiwu Yu, Lei Zheng, Qian Wang

NSCLC Original Article

Multi-institutional feasibility study of intensity-modulated radiotherapy with chemotherapy for locally advanced non-small cell lung cancer

Hideyuki Harada, Shota Omori, Keita Mori, Masahiro Konno, Haruyasu Murakami, Toshiyuki Imagumbai, Haruyuki Fukuda, Kiyoshi Nakamatsu, Tomoki Kimura, Hiroaki Tanabe, Hideki Fujita, Hitoshi Tatebe, Kazunori Fujitaka, Yasumasa Nishimura

Ovarian Cancer Original Article

Recent trends in the morbidity and mortality in patients with familial adenomatous polyposis: a retrospective single institutional study in Japan

Yoshiko Mori, Kunihiko Amano, Kenichi Chikatani, Tetsuya Ito, Okihide Suzuki, Nao Kamae, Satoshi Hatano, Noriyasu Chika, Azusa Yamamoto, Keiichiro Ishibashi, Hidetaka Eguchi, Yasushi Okazaki, Takeo Iwama, Hideyuki Ishida

Rectal Cancer Original Article

Risk of first onset of colorectal cancer associated with alcohol consumption in Lynch syndrome: a multicenter cohort study

Kenji Fujiyoshi, Tomoya Sudo, Fumihiko Fujita, Akiko Chino, Kiwamu Akagi, Akinari Takao, Masayoshi Yamada, Kohji Tanakaya, Hideyuki Ishida, Koji Komori, Soichiro Ishihara, Masashi Miguchi, Keiji Hirata, Yasuyuki Miyakura, Toshiaki Ishikawa, Tatsuro Yamaguchi, Naohiro Tomita, Yoichi Ajioka, Kenichi Sugihara

Correction to: Risk of first onset of colorectal cancer associated with alcohol consumption in Lynch syndrome: a multicenter cohort study

Kenji Fujiyoshi, Tomoya Sudo, Fumihiko Fujita, Akiko Chino, Kiwamu Akagi, Akinari Takao, Masayoshi Yamada, Kohji Tanakaya, Hideyuki Ishida, Koji Komori, Soichiro Ishihara, Masashi Miguchi, Keiji Hirata, Yasuyuki Miyakura, Toshiaki Ishikawa, Tatsuro Yamaguchi, Naohiro Tomita, Yoichi Ajioka, Kenichi Sugihara

Open Access Kidney Cancer Original Article

Real-world safety and effectiveness of nivolumab for advanced renal cell carcinoma in Japan: a post-marketing surveillance

Hirotsugu Uemura, Yoshihiko Tomita, Norio Nonomura, Kenji Yoshizaki, Takafumi Nakao, Nobuo Shinohara

Nephrectomy Original Article

Survival after minimally invasive vs. open radical nephrectomy for stage I and II renal cell carcinoma

Furkan Dursun, Ahmed Elshabrawy, Hanzhang Wang, Ronald Rodriguez, Michael A. Liss, Dharam Kaushik, Jonathan Gelfond, Ahmed M. Mansour

Prostate Cancer Original Article

Incidental prostate cancer after holmium laser enucleation of the prostate: incidence and predictive factors for clinical progression

Clément Klein, Thibault Marquette, Grégoire Capon, Mokrane Yacoub, Eric Alezra, Jean-Christophe Bernhard, Franck Bladou, Grégoire Robert

Laparotomy Original Article

Oncologic outcomes in elderly patients who underwent hysterectomy for endometrial cancer: a multi-institutional survey in Kinki District, Japan

Tomohito Tanaka, Suguru Yamashita, Haruo Kuroboshi, Junya Kamibayashi, Atsushi Sugiura, Kaori Yoriki, Taisuke Mori, Kazuharu Tanaka, Aiko Nagashima, Michihide Maeda, Shoji Kamiura, Yukako Mizuno, Noriko Ohtake, Tomoyuki Ichimura, Taiki Kikuchi, Yuri Nobuta, Tsukuru Amano, Noriomi Matsumura, Hidekatsu Nakai, Eiji Kobayashi, Yuji Kamei, Masayo Ukita, Junzo Hamanishi, Junya Hirayama, Yasushi Mabuchi, Seiko Kato, Hiroyuki Fujita, Atsuko Kiyota, Shinsuke Koyama, Yosuke Fukui, Mai Kimura, Ryosuke Takahashi, Yoshito Terai, Madoka Suruga, Masaru Kawanishi, Kazuhiro Nishioka, Masahide Ohmichi

Liposarcoma Original Article

The clinical significance of perioperative inflammatory index as a prognostic factor for patients with retroperitoneal soft tissue sarcoma

Yoshiyuki Matsui, Ayumu Matsuda, Aiko Maejima, Yasuo Shinoda, Eijiro Nakamura, Motokiyo Komiyama, Hiroyuki Fujimoto

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine